RPRX
Royalty Pharma plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
26.99
PEG
—
P/B
3.24
P/S
8.75
EV/EBITDA
17.83
DCF Value
$28.89
FCF Yield
12.0%
Div Yield
1.8%
Margins & Returns
Gross Margin
100.0%
Operating Margin
65.6%
Net Margin
32.4%
ROE
11.9%
ROA
4.1%
ROIC
8.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $622.0M | $214.2M | $0.50 |
| FY 2025 | $2.38B | $770.9M | $1.80 |
| Q3 2025 | $609.3M | $288.2M | $0.67 |
| Q2 2025 | $578.7M | $30.2M | $0.07 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.39
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.